(Q69452377)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3682956%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

title

Antifungal agents used for deep-seated mycotic infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3682956%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

author name string

C L Terrell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3682956%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

P E Hermans

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3682956%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

publication date

1 December 1987

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3682956%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3682956%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3682956%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3682956%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

page(s)

1116-1128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3682956%20AND%20SRC:MED&resulttype=core&format=json

Studies on the biological properties of polyene antibiotics: Comparison of other polyenes with filipin in their ability to interact specifically with sterol

2 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

A pharmacologic guide to the clinical use of amphotericin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Cryptococcosis, with Emphasis on the Significance of Isolation of Cryptococcus neoformans from the Respiratory Tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Therapy of Cryptococcosis with a Combination of Flucytosine and Amphotericin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Sporotrichosis arthritis: clinical features in seven patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Primary Renal Candida Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Asymptomatic Candiduria: Prognosis, Complications and some other Clinical Considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Renal Tubular Acidosis Due to Amphotericin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Endogenous Candida oculomycosis. Report of two patients treated with flucytosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

5-fluorocytosine in the treatment of cryptococcal and candida mycoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

5-fluorocytosine: an oral antifungal compound. A report on clinical and laboratory experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

5-Fluorocytosine Treatment of Candida Infections of the Urinary Tract and Other Sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Synergism of Amphotericin B and 5-Fluorocytosine for Candida Species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

The influence of gastric acidity on the bio-availability of ketoconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Influence of food on the pharmacokinetics of ketoconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Impairing effect of food on ketoconazole absorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Liquid chromatographic assay of ketoconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Treatment of Coccidioidomycosis with Ketoconazole: Clinical and Laboratory Studies of 18 Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Disposition of ketoconazole, an oral antifungal, in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Laboratory and clinical assessment of ketoconazole in deep-seated mycoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

An Evaluation of Two Years of Clinical Experience with Ketoconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Progressive Disseminated Histoplasmosis: Favorable Response to Ketoconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Treatment of disseminated and progressive cavitary histoplasmosis with ketoconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Ketoconazole therapy for endemic blastomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Cutaneous, ocular, and osteoarticular candidiasis in heroin addicts: new clinical and therapeutic aspects in 38 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Ketoconazole for Treatment of Disseminated Coccidioidomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Ketoconazole for treatment of chronic pulmonary coccidioidomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

High-Dose Ketoconazole for Treatment of Fungal Infections of the Central Nervous System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Failure of Ketoconazole in Cryptococcal Meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Pseudallescheria boydii infections treated with ketoconazole. Clinical evaluations of seven patients and in vitro susceptibility results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Efficacy of Ketoconazole v Nystatin in Prevention of Fungal Infections in Neutropenic Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Ketoconazole Blocks Adrenal Steroid Synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Potentiation of oral anticoagulants by ketoconazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Treatment of Murine Pulmonary Cryptococcosis with Ketoconazole and Amphotericin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Deep infections from Petriellidium boydii treated with miconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Successful medical treatment of pulmonary petriellidiosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Treatment of fungal meningitis with miconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Miconazole in the Treatment of Coccidioidomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Miconazole in Cryptococcosis and Systemic Candidiasis: A Word of Caution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Paracoccidioidomycosis (South American blastomycosis): treatment with miconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Cardiorespiratory toxicity due to miconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

In vitro studies with R 51,211 (itraconazole)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Itraconazole for cryptococcal infection in the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Itraconazole, a new triazole that is orally active in aspergillosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

7 January 2021

Chronic Mucocutaneous Candidosis and Other Superficial and Systemic Mycoses Successfully Treated with Ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

7 January 2021

Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

7 January 2021

Phenytoin intoxication during treatment with parenteral miconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

7 January 2021

Itraconazole: pharmacologic studies in animals and humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962506-3

7 January 2021

10.1016/S0025-6196(12)62506-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3682956%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

1 reference